Lexicon Pharma (LXRX) Tops Q4 EPS by 3c

Lexicon Pharma (NASDAQ: LXRX) reported Q4 EPS of $0.00, $0.03 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $21.4 million versus the consensus estimate of $11.97 million.

For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.

You May Also Be Interested In

• L3Harris CEO steps down amid conduct review, shares drop
• InspireMD (NSPR) Tops Q2 EPS by 1c
• INVO Fertility (IVF) Tops Q2 EPS by 105c